

Clinical Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Segmented By Product (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), By Services (Genomic Biomarker Service, Tissue Biomarker Service, Cell Service, Proteomics Service), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, Enzyme-Linked Immunosorbent Assay, Others), By Clinical Area (Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Others), By Application (Translational Research v/s Clinical Diagnostics), By End User (Biotechnology & Pharmaceutical Companies, Diagnostic Centers, Academic & Research Institutions, Others), By company and By Region

Market Report | 2023-06-01 | 112 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

The global clinical biomarkers market is anticipated to observe impressive growth during the forecast period, 2023-2027. The

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

major factors include growing occurrences of infectious diseases and various types of cancer, and extensive development in technology is propelling the growth of the market. Clinical biomarkers are widely preferred in the field of clinical medicine to provide personalized treatment choices to patients. Biomarkers are essential to the rational development of medical therapeutics and are engaged in their use in in-vitro diagnostics purposes, especially in the fields of chronic disease and nutrition. The other factors supporting the market's growth are, rise in R&D activities, increasing demand for personalized treatment, increasing favorable government funding, the rising healthcare burden, rise in the aging population base, increasing demand for clinical biomarker products, a growing number of mergers and strategic acquisitions, and rise in the number of patients.

Increasing Prevalence of Infectious Diseases and Various Types of Cancer

The increasing occurrence of infectious diseases and various types of cancer across the globe is bolstering the growth of the market. A large number of people are suffering from various infectious diseases and cancers, due to which there is a surge in demand for clinical biomarkers products, which is facilitating the growth of the market. The utilization of clinical biomarkers helps to diagnose and monitor the disease and also helps to identify the patient at risk for a serious adverse event or to benefit from drug treatment. According to the Centers for Disease Control and Prevention (CDC), in 2018, 1.7 billion people were infected by TB bacteria, which is approximately 23% of the world's population. TB is the leading infectious disease in the world, taking 1.5 million lives every year. Similarly, in 2021, about 235,760 lung cancer cases were registered in the U.S. Additionally, in the U.S., over 130,000 people die every year due to lung cancer.

Technological Advancements and Rise in R&D Activities

In recent years, the adoption of highly advanced technology has allowed biomarkers to couple with novel drugs for successful diagnosis and effective treatment alternatives. For instance, in 2018, Abcam Plc., a global life sciences company, launched its product FirePlex HT Immunoassay for the quick detection of neurological biomarkers. Moreover, the rise in research and development for improving the effectiveness of clinical biomarkers is augmenting the growth of the market. For instance, in 2022, a University of Oxford study published in the Clinical Cancer Research Journal described a new type of blood test that can be utilized to detect a range of cancers and their spread in the human body. The study was done on 300 patients with non-specific but concerning symptoms of cancer, such as weight loss and fatigue. As per the study, cancer was properly detected in 19 out of every 20 patients that used the test. Metastatic disease was identified with an accuracy of 94%.

Market Segmentation

The global clinical biomarkers market is segmented into products, services, technology, clinical area, application, end user, and company. Based on the product, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. Based on services, the market is divided into genomic biomarker services, tissue biomarker services, cell service, and proteomics services. Based on technology, the market is divided into next-generation sequencing, polymerase chain reaction, immunohistochemistry, enzyme-linked immunosorbent assay, and others. Based on clinical area, the market is divided into cancer biomarkers, cardiac biomarker, neurological biomarkers, infectious disease biomarkers, and others. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, diagnostic centers, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in the adoption rate of novel technology in the country.

Market Players

Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche AG, QIAGEN NV, PerkinElmer, Inc, Thermo Fischer Scientific, Inc., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., Charles River Laboratories International, Inc., Quest Diagnostics, Inc., Abbott Laboratories, Inc., Enzo Biochem Inc., Myriad Genetics, Inc., CENTOGENE N.V., and bioMerieux S.A. are some of the leading companies operating in the market.

Report Scope:

In this report, global clinical biomarkers market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

-□ Clinical Biomarkers Market, By Product:

o□ Efficacy Biomarkers

o□ Safety Biomarkers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Validation Biomarkers
- Clinical Biomarkers Market, By Services: -
 - o Genomic Biomarker Service
 - o Tissue Biomarker Service
 - o Cell Service,
 - o Proteomics Service
- Clinical Biomarkers Market, By Technology:
 - o Next-Generation Sequencing
 - o Polymerase Chain Reaction, Immunohistochemistry
 - o Enzyme-Linked Immunosorbent Assay
 - o Others
- Clinical Biomarkers Market, By Clinical Area: -
 - o Cancer Biomarker
 - o Cardiac Biomarker
 - o Neurological Biomarker
 - o Infectious Disease Biomarker
 - o Others
- Clinical Biomarkers Market, By Application:
 - o Translational Research
 - o Clinical Diagnostics
- Clinical Biomarkers Market, By End User: -
 - o Biotechnology & Pharmaceutical Companies
 - o Diagnostic Centers
 - o Academic & Research Institutions
 - o Others
- Clinical Biomarkers Market, By Region:
 - o North America
 - United States
 - Canada
 - Mexico
 - o Asia-Pacific
 - China
 - India
 - Japan
 - Australia
 - South Korea
 - o Europe & CIS
 - Germany
 - France
 - United Kingdom
 - Spain
 - Italy
 - o South America
 - Brazil
 - Argentina
 - Colombia
 - o Middle East & Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Clinical Biomarkers Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

- 1.□Product Overview
- 2.□Research Methodology
- 3.□Executive Summary
- 4.□Impact of COVID-19 on Global Clinical Biomarkers Market
- 5.□Voice of Customer
- 6.□Global Clinical Biomarkers Market Outlook
 - 6.1.□Market Size & Forecast
 - 6.1.1.□By Value
 - 6.2.□Market Share & Forecast
 - 6.2.1.□By Product (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers)
 - 6.2.2.□By Services (Genomic Biomarker Service, Tissue Biomarker Service, Cell Service, Proteomics Service)
 - 6.2.3.□By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, Enzyme-Linked Immunosorbent Assay, Others)
 - 6.2.4.□By Clinical Area (Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Others)
 - 6.2.5.□By Application (Translational Research v/s Clinical Diagnostics)
 - 6.2.6.□By End User (Biotechnology & Pharmaceutical Companies, Diagnostic Centers, Academic & Research Institutions, Others)
 - 6.2.7.□By Region
 - 6.2.8.□By Company (2021)
 - 6.3.□Market Map
- 7.□North America Clinical Biomarkers Market Outlook
 - 7.1.□Market Size & Forecast
 - 7.1.1.□By Value
 - 7.2.□Market Share & Forecast
 - 7.2.1.□By Product
 - 7.2.2.□By Services
 - 7.2.3.□By Technology
 - 7.2.4.□By Clinical Area
 - 7.2.5.□By Application
 - 7.2.6.□By End User
 - 7.2.7.□By Country
 - 7.3.□North America: Country Analysis
 - 7.3.1.□United States Clinical Biomarkers Market Outlook
 - 7.3.1.1.□Market Size & Forecast
 - 7.3.1.1.1.□By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.1.2.□Market Share & Forecast
 - 7.3.1.2.1.□By Product
 - 7.3.1.2.2.□By Services
 - 7.3.1.2.3.□By Technology
 - 7.3.1.2.4.□By Clinical Area
 - 7.3.1.2.5.□By Application
 - 7.3.1.2.6.□By End User
- 7.3.2.□Canada Clinical Biomarkers Market Outlook
 - 7.3.2.1.□Market Size & Forecast
 - 7.3.2.1.1.□By Value
 - 7.3.2.2.□Market Share & Forecast
 - 7.3.2.2.1.□By Product
 - 7.3.2.2.2.□By Services
 - 7.3.2.2.3.□By Technology
 - 7.3.2.2.4.□By Clinical Area
 - 7.3.2.2.5.□By Application
 - 7.3.2.2.6.□By End User
- 7.3.3.□Mexico Clinical Biomarkers Market Outlook
 - 7.3.3.1.□Market Size & Forecast
 - 7.3.3.1.1.□By Value
 - 7.3.3.2.□Market Share & Forecast
 - 7.3.3.2.1.□By Product
 - 7.3.3.2.2.□By Services
 - 7.3.3.2.3.□By Technology
 - 7.3.3.2.4.□By Clinical Area
 - 7.3.3.2.5.□By Application
 - 7.3.3.2.6.□By End User
- 8.□Europe Clinical Biomarkers Market Outlook
 - 8.1.□Market Size & Forecast□
 - 8.1.1.□By Value
 - 8.2.□Market Share & Forecast
 - 8.2.1.□By Product
 - 8.2.2.□By Services
 - 8.2.3.□By Technology
 - 8.2.4.□By Clinical Area
 - 8.2.5.□By Application
 - 8.2.6.□By End User
 - 8.2.7.□By Country
 - 8.3.□Europe: Country Analysis
 - 8.3.1.□France Clinical Biomarkers Market Outlook
 - 8.3.1.1.□Market Size & Forecast
 - 8.3.1.1.1.□By Value
 - 8.3.1.2.□Market Share & Forecast
 - 8.3.1.2.1.□By Product
 - 8.3.1.2.2.□By Services
 - 8.3.1.2.3.□By Technology
 - 8.3.1.2.4.□By Clinical Area

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.1.2.5.□By Application
- 8.3.1.2.6.□By End User
- 8.3.2.□Germany Clinical Biomarkers Market Outlook
- 8.3.2.1.□Market Size & Forecast
- 8.3.2.1.1.□By Value
- 8.3.2.2.□Market Share & Forecast
- 8.3.2.2.1.□By Product
- 8.3.2.2.2.□By Services
- 8.3.2.2.3.□By Technology
- 8.3.2.2.4.□By Clinical Area
- 8.3.2.2.5.□By Application
- 8.3.2.2.6.□By End User
- 8.3.3.□United Kingdom Clinical Biomarkers Market Outlook
- 8.3.3.1.□Market Size & Forecast
- 8.3.3.1.1.□By Value
- 8.3.3.2.□Market Share & Forecast
- 8.3.3.2.1.□By Product
- 8.3.3.2.2.□By Services
- 8.3.3.2.3.□By Technology
- 8.3.3.2.4.□By Clinical Area
- 8.3.3.2.5.□By Application
- 8.3.3.2.6.□By End User
- 8.3.4.□Italy Clinical Biomarkers Market Outlook
- 8.3.4.1.□Market Size & Forecast
- 8.3.4.1.1.□By Value
- 8.3.4.2.□Market Share & Forecast
- 8.3.4.2.1.□By Product
- 8.3.4.2.2.□By Services
- 8.3.4.2.3.□By Technology
- 8.3.4.2.4.□By Clinical Area
- 8.3.4.2.5.□By Application
- 8.3.4.2.6.□By End User
- 8.3.5.□Spain Clinical Biomarkers Market Outlook
- 8.3.5.1.□Market Size & Forecast
- 8.3.5.1.1.□By Value
- 8.3.5.2.□Market Share & Forecast
- 8.3.5.2.1.□By Product
- 8.3.5.2.2.□By Services
- 8.3.5.2.3.□By Technology
- 8.3.5.2.4.□By Clinical Area
- 8.3.5.2.5.□By Application
- 8.3.5.2.6.□By End User
- 9.□Asia-Pacific Clinical Biomarkers Market Outlook
- 9.1.□Market Size & Forecast□
- 9.1.1.□By Value
- 9.2.□Market Share & Forecast
- 9.2.1.□By Product

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.2.□By Services
- 9.2.3.□By Technology
- 9.2.4.□By Clinical Area
- 9.2.5.□By Application
- 9.2.6.□By End User
- 9.2.7.□By Country
- 9.3.□Asia-Pacific: Country Analysis
- 9.3.1.□China Clinical Biomarkers Market Outlook
 - 9.3.1.1.□Market Size & Forecast
 - 9.3.1.1.1.□By Value
 - 9.3.1.2.□Market Share & Forecast
 - 9.3.1.2.1.□By Product
 - 9.3.1.2.2.□By Services
 - 9.3.1.2.3.□By Technology
 - 9.3.1.2.4.□By Clinical Area
 - 9.3.1.2.5.□By Application
 - 9.3.1.2.6.□By End User
- 9.3.2.□India Clinical Biomarkers Market Outlook
 - 9.3.2.1.□Market Size & Forecast
 - 9.3.2.1.1.□By Value
 - 9.3.2.2.□Market Share & Forecast
 - 9.3.2.2.1.□By Product
 - 9.3.2.2.2.□By Services
 - 9.3.2.2.3.□By Technology
 - 9.3.2.2.4.□By Clinical Area
 - 9.3.2.2.5.□By Application
 - 9.3.2.2.6.□By End User
- 9.3.3.□Japan Clinical Biomarkers Market Outlook
 - 9.3.3.1.□Market Size & Forecast
 - 9.3.3.1.1.□By Value
 - 9.3.3.2.□Market Share & Forecast
 - 9.3.3.2.1.□By Product
 - 9.3.3.2.2.□By Services
 - 9.3.3.2.3.□By Technology
 - 9.3.3.2.4.□By Clinical Area
 - 9.3.3.2.5.□By Application
 - 9.3.3.2.6.□By End User
- 9.3.4.□South Korea Clinical Biomarkers Market Outlook
 - 9.3.4.1.□Market Size & Forecast
 - 9.3.4.1.1.□By Value
 - 9.3.4.2.□Market Share & Forecast
 - 9.3.4.2.1.□By Product
 - 9.3.4.2.2.□By Services
 - 9.3.4.2.3.□By Technology
 - 9.3.4.2.4.□By Clinical Area
 - 9.3.4.2.5.□By Application
 - 9.3.4.2.6.□By End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.5.□Australia Clinical Biomarkers Market Outlook
 - 9.3.5.1.□Market Size & Forecast
 - 9.3.5.1.1.□By Value
 - 9.3.5.2.□Market Share & Forecast
 - 9.3.5.2.1.□By Product
 - 9.3.5.2.2.□By Services
 - 9.3.5.2.3.□By Technology
 - 9.3.5.2.4.□By Clinical Area
 - 9.3.5.2.5.□By Application
 - 9.3.5.2.6.□By End User
- 10.□South America Clinical Biomarkers Market Outlook
 - 10.1.□Market Size & Forecast□
 - 10.1.1.□By Value
 - 10.2.□Market Share & Forecast
 - 10.2.1.□By Product
 - 10.2.2.□By Services
 - 10.2.3.□By Technology
 - 10.2.4.□By Clinical Area
 - 10.2.5.□By Application
 - 10.2.6.□By End User
 - 10.2.7.□By Country
 - 10.3.□South America: Country Analysis
 - 10.3.1.□Brazil Clinical Biomarkers Market Outlook
 - 10.3.1.1.□Market Size & Forecast
 - 10.3.1.1.1.□By Value
 - 10.3.1.2.□Market Share & Forecast
 - 10.3.1.2.1.□By Product
 - 10.3.1.2.2.□By Services
 - 10.3.1.2.3.□By Technology
 - 10.3.1.2.4.□By Clinical Area
 - 10.3.1.2.5.□By Application
 - 10.3.1.2.6.□By End User
 - 10.3.2.□Argentina Clinical Biomarkers Market Outlook
 - 10.3.2.1.□Market Size & Forecast
 - 10.3.2.1.1.□By Value
 - 10.3.2.2.□Market Share & Forecast
 - 10.3.2.2.1.□By Product
 - 10.3.2.2.2.□By Services
 - 10.3.2.2.3.□By Technology
 - 10.3.2.2.4.□By Clinical Area
 - 10.3.2.2.5.□By Application
 - 10.3.2.2.6.□By End User
 - 10.3.3.□Colombia Clinical Biomarkers Market Outlook
 - 10.3.3.1.□Market Size & Forecast
 - 10.3.3.1.1.□By Value
 - 10.3.3.2.□Market Share & Forecast
 - 10.3.3.2.1.□By Product

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.3.2.2.□By Services
- 10.3.3.2.3.□By Technology
- 10.3.3.2.4.□By Clinical Area
- 10.3.3.2.5.□By Application
- 10.3.3.2.6.□By End User
- 11.□Middle East and Africa Clinical Biomarkers Market Outlook
- 11.1.□Market Size & Forecast□
- 11.1.1.□By Value
- 11.2.□Market Share & Forecast
- 11.2.1.□By Product
- 11.2.2.□By Services
- 11.2.3.□By Technology
- 11.2.4.□By Clinical Area
- 11.2.5.□By Application
- 11.2.6.□By End User
- 11.2.7.□By Country
- 11.3.□MEA: Country Analysis
- 11.3.1.□South Africa Clinical Biomarkers Market Outlook
- 11.3.1.1.□Market Size & Forecast
- 11.3.1.1.1.□By Value
- 11.3.1.2.□Market Share & Forecast
- 11.3.1.2.1.□By Product
- 11.3.1.2.2.□By Services
- 11.3.1.2.3.□By Technology
- 11.3.1.2.4.□By Clinical Area
- 11.3.1.2.5.□By Application
- 11.3.1.2.6.□By End User
- 11.3.2.□Saudi Arabia Clinical Biomarkers Market Outlook
- 11.3.2.1.□Market Size & Forecast
- 11.3.2.1.1.□By Value
- 11.3.2.2.□Market Share & Forecast
- 11.3.2.2.1.□By Product
- 11.3.2.2.2.□By Services
- 11.3.2.2.3.□By Technology
- 11.3.2.2.4.□By Clinical Area
- 11.3.2.2.5.□By Application
- 11.3.2.2.6.□By End User
- 11.3.3.□UAE Clinical Biomarkers Market Outlook
- 11.3.3.1.□Market Size & Forecast
- 11.3.3.1.1.□By Value
- 11.3.3.2.□Market Share & Forecast
- 11.3.3.2.1.□By Product
- 11.3.3.2.2.□By Services
- 11.3.3.2.3.□By Technology
- 11.3.3.2.4.□By Clinical Area
- 11.3.3.2.5.□By Application
- 11.3.3.2.6.□By End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12. □Market Dynamics
 - 12.1. □Drivers
 - 12.2. □Challenges
- 13. □Market Trends & Developments
- 14. □Competitive Landscape (Inclusive of SWOT Analysis)
 - 14.1. □Agilent Technologies, Inc.
 - 14.2. □Illumina, Inc.
 - 14.3. □F. Hoffmann-La Roche AG
 - 14.4. □QIAGEN NV
 - 14.5. □PerkinElmer, Inc
 - 14.6. □Thermo Fischer Scientific, Inc.
 - 14.7. □Bio-Rad Laboratories, Inc.
 - 14.8. □NeoGenomics Laboratories, Inc.
 - 14.9. □Charles River Laboratories International, Inc.
 - 14.10. □Quest Diagnostics, Inc.
 - 14.11. □Abbott Laboratories, Inc.
 - 14.12. □Enzo Biochem Inc.
 - 14.13. □Myriad Genetics, Inc.
 - 14.14. □CENTOGENE N.V.
 - 14.15. □bioMerieux S.A.
- 15. □Strategic Recommendations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Clinical Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Segmented By Product (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), By Services (Genomic Biomarker Service, Tissue Biomarker Service, Cell Service, Proteomics Service), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, Enzyme-Linked Immunosorbent Assay, Others), By Clinical Area (Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Others), By Application (Translational Research v/s Clinical Diagnostics), By End User (Biotechnology & Pharmaceutical Companies, Diagnostic Centers, Academic & Research Institutions, Others), By company and By Region

Market Report | 2023-06-01 | 112 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com


ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784


tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784


tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	<div></div>